Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Stock
Stocks
600196
CNE000000X38
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.40 CNY | -5.30% |
|
-0.21% | -11.66% |
| 07-16 | Fosun Pharma Unit Gets China Clinical Trial Approval for Triglyceride Drug Candidate | MT |
| 07-01 | Junshi Biosciences Licenses Autoimmune Drug to Fosun Pharma | MT |
| Market Cap | 56.69B 8.36B 7.31B 6.74B 6.22B 11.72B 805B 11.98B 80.62B 31.71B 394B 31.41B 30.72B 1,358B | P/E 2026 * |
15.8x | P/E 2027 * | 13.9x |
|---|---|---|---|---|---|
| Enterprise Value | 67.49B 9.96B 8.7B 8.03B 7.4B 13.95B 959B 14.26B 95.98B 37.75B 470B 37.4B 36.58B 1,617B | EV / Sales 2026 * |
1.56x | EV / Sales 2027 * | 1.73x |
| Free-Float |
62.77% | Yield 2026 * |
1.9% | Yield 2027 * | 2.19% |
| 1 day | -5.30% | ||
| 1 week | -0.21% | ||
| Current month | +4.14% | ||
| 1 month | +8.43% | ||
| 3 months | -10.52% | ||
| 6 months | -15.19% | ||
| Current year | -11.66% |
| 1 week | 23.25 |  | 25.18 |
| 1 month | 20.85 | | 25.18 |
| Current year | 20.85 | | 28.71 |
| 1 year | 20.85 | | 33.1 |
| 3 years | 20.38 | | 33.1 |
| 5 years | 20.38 | | 91.69 |
| 10 years | 20.38 | | 91.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yi Liu
CEO | Chief Executive Officer | 50 | 2025-06-23 |
Zhi Huang
DFI | Director of Finance/CFO | - | 2026-04-01 |
Wang Xing Li
PSD | President | 63 | 2022-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Qi Yu Chen
CHM | Chairman | 54 | 1994-03-31 |
Peng Hui Chen
BRD | Director/Board Member | 55 | 2025-06-23 |
Yi Min Guan
BRD | Director/Board Member | 76 | 2014-05-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 5/30/25 | Sell | Public Communications Manager | 31,790 | 0.0015% | ||
| 5/30/25 | Sell | Chief Executive Officer | 87,448 | 0.0041% | ||
| 5/30/25 | Sell | Director | 63,614 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.30% | -0.21% | -11.36% | -23.13% | 8.36B | |
| +0.85% | -0.80% | +54.84% | +163.70% | 1,051B | |
| +1.23% | -1.53% | +55.26% | +59.07% | 609B | |
| +0.04% | +2.58% | +32.96% | +88.75% | 450B | |
| +0.78% | -0.71% | +30.04% | +24.61% | 330B | |
| +1.41% | +0.58% | +33.92% | +47.20% | 284B | |
| -0.27% | -1.87% | +22.13% | +23.47% | 263B | |
| -1.76% | +2.37% | -22.19% | -38.45% | 223B | |
| -1.42% | +0.80% | +22.81% | +60.77% | 198B | |
| -1.48% | +3.43% | +23.42% | +73.31% | 167B | |
| Average | -0.64% | +0.32% | +24.18% | +47.93% | 358.34B | |
| Weighted average by Cap. | +0.20% | +0.02% | +37.64% | +81.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 43.32B 6.39B 5.59B 5.15B 4.75B 8.95B 616B 9.15B 61.61B 24.23B 301B 24B 23.48B 1,038B | 43.44B 6.41B 5.6B 5.17B 4.76B 8.98B 617B 9.18B 61.77B 24.3B 302B 24.07B 23.54B 1,041B |
| Net income | 3.87B 570M 498M 460M 424M 799M 54.92B 817M 5.5B 2.16B 26.9B 2.14B 2.09B 92.59B | 4.27B 630M 551M 508M 468M 883M 60.7B 903M 6.07B 2.39B 29.73B 2.37B 2.32B 102B |
| Net Debt | 10.8B 1.59B 1.39B 1.29B 1.18B 2.23B 153B 2.28B 15.36B 6.04B 75.16B 5.98B 5.85B 259B | 18.28B 2.7B 2.36B 2.17B 2B 3.78B 260B 3.86B 26B 10.22B 127B 10.13B 9.91B 438B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-17 | CN¥23.40 | -5.30% | 48,012,852 |
| 26-07-16 | CN¥24.71 | -0.52% | 49,605,568 |
| 26-07-15 | CN¥24.84 | +3.28% | 59,638,876 |
| 26-07-14 | CN¥24.05 | +1.09% | 39,577,476 |
| 26-07-13 | CN¥23.79 | +1.45% | 37,517,578 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 600196 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
